• Pacsun and Ulta Beauty have already rolled out an exclusive Pacsun x Ulta Beauty capsule across stores and online, while Ulta has recently backed several category-expanding launches, including plusOne sexual wellness products, Peach & Lily’s “Zombie Cream,” and Ice Spice’s debut fragrance with Revlon.
• Together, these collaborations and exclusive launches reinforce Ulta Beauty’s role as a key platform where fashion, wellness, science-led skincare, and celebrity-driven products intersect for younger shoppers.
• We’ll now examine how Ulta’s Pacsun partnership, blending fashion with curated beauty kits, could influence the company’s broader investment narrative.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Ulta Beauty Investment Narrative Recap

To own Ulta Beauty, you generally need to believe it can keep using its store base, loyalty program, and brand partnerships to pull in younger shoppers while managing rising costs and competitive pressures. The Pacsun collaboration, plus recent exclusive launches, fits neatly into the existing catalyst around assortment expansion and Gen Z reach, but it does not fundamentally alter the near term focus on cost control, store productivity, and the looming Target partnership sunset risk.

Among the recent announcements, the expansion of Ulta’s wellness footprint through plusOne sexual wellness products looks especially relevant next to the Pacsun capsule. Both speak directly to Ulta’s effort to be a one stop destination for younger consumers who think about beauty, fashion, and wellness together, which ties back to the key growth catalysts around wellness, exclusive brands, and differentiated in store experiences, even as cost inflation and physical store economics remain key watchpoints.

But against these appealing partnerships, investors should still pay close attention to how rising wage and occupancy costs could pressure margins and...

Ulta Beauty's narrative projects $14.9 billion revenue and $1.4 billion earnings by 2029. This requires 5.4% yearly revenue growth and about a $0.2 billion earnings increase from $1.2 billion today.

Uncover how Ulta Beauty's forecasts yield a $627.25 fair value, a 23% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling Ulta at about US$15.1 billion in revenue and US$1.5 billion in earnings by 2029, so announcements like Pacsun x Ulta Beauty and wellness expansions could either support that view or prompt a rethink, especially if you worry about execution risk around product complexity and guest experience.

Explore 5 other fair value estimates on Ulta Beauty - why the stock might be worth as much as 25% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ulta Beauty research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Ulta Beauty research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ulta Beauty's overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.